The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia

Kardiologia Polska

Volumn 62, Issue 6, 2005, Pages 526-530

  Yesilbursa, Dilek ^a   Serdar, Akin ^a   Saltan, Yelda ^a   Serdar, Zehra ^a   Heper, Yasemin ^a   Guclu, Sevil ^a   Cordan, Jale ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Combined hyperlipidemia; Fenofibrate; Inflammatory markers; Paraoxonase

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID BLOOD LEVEL; MALE; TREATMENT OUTCOME;

EID: 21844447616     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ross R.: Atherosclerosis - an inflammatory disease. N. Eng. J. Med. 1999, 340, 115-126.
2. Ernst E., Resch K.L.: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Int. Med. 1993, 118, 956-63.
3. Ridker P.M., Haughie P.: Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J. Investig. Med. 1998, 46, 391-395.
4. Mackness M.I., Arrol S., Abbott C.A. et al.: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993, 104, 129-135.
5. Mackness M.I., Durrington P.N.: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995, 115, 243-253.
6. Mackness M.I., Durrington P.N., Ayub A. et al.: Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem. Biol. Interact. 1999, 119-120, 389-397.
7. Hokanson J.E., Austin M.A.: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population based prospective studies. J. Cardiovasc. Risk 1996, 3, 213-219.
8. Ruotolo G., Ericsson C.G., Tettamanti C. et al.: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Am. J. Coll. Cardiol. 1998, 32, 1648-1656.
9. Vaughan C.J., Murphy M.B., Buckley B.M.: Statins do more than just lower cholesterol. Lancet 1996, 348, 1079-1082.
10. Friedewald W.T., Levy R.I., Fredericksen D.S.: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin. Chem. 1972, 18 (6), 499-502.
11. Eckerson H.W., Wyto CM., La Du B.N.: The human serum paraoxonase/ arylesterase polymorphism. Am. J. Hum. Genet. 1983, 35, 1126-1138.
12. Klosiewicz-Latoszek L., Szostak W.B., Grzybowska B. et al.: Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia. Kardiol. Pol. 2004, 60, 567-77.
13. Chaput E., Maubrou-Sanchez D., Bellamy F.D. et al.: Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with alpha-tocopherol. Lipids 1999, 34, 497-502.
14. Balogh Z., Seres I., Harangi M. et al.: Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab. 2001, 27, 604-610.
15. Durrington P.N., Mackness M.I., Bhatnagar D. et al.: Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type lib hyperlipoproteinaemia. Atherosclerosis. 1998, 138, 217-225.
16. Tomas M., Senti M., Garcia-Faria F. et al.: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolaemic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2113-2119.
17. Abbott C.A., Mackness M.I., Kumar S. et al.: Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1812-1818.
18. Stein J.H., Rosenson R.S. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 1998, 137, 401-405.
19. Ericsson C.G., Hamsten A., Nilsson J. et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347, 849-853.
20. Frost R.J.A., Otto C., Geiss C. et al.: Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 2001, 87, 44-48.
21. Rizos E., Kostoula A., Elisaf M. et al.: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002, 53 (3), 273-7.
22. Jonkers I.J., Mohrschladt M.F., Westendorp R.G. et al.: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled study. Am. J. Med. 2002, 112, 275-280.
23. Albert M.A., Danielson E., Rifai N. et al.: Effect of statin therapy on C-reactive protein levels. JAMA 2001, 286, 64-70.